Fox Run Management’s Immunovant IMVT Stock Holding History

Fox Run Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Buy	+34,827	New	+$1.06M	0.22%	93
2025 Q2	–	Sell	-13,428	Closed	-$229K	–	1030
2025 Q1	$229K	Buy	+13,428	New	+$281K	0.04%	759
2024 Q1	–	Sell	-14,534	Closed	-$612K	–	916
2023 Q4	$612K	Buy	+14,534	New	+$535K	0.16%	226
2023 Q2	–	Sell	-12,882	Closed	-$200K	–	815
2023 Q1	$200K	Buy	12,882 +102	+0.8%	+$1.77K	0.07%	532
2022 Q4	$227K	Buy	+12,780	New	+$161K	0.09%	450
2022 Q1	–	Sell	-10,803	Closed	-$92K	–	603
2021 Q4	$92K	Sell	10,803 -3,109	-22%	-$25.7K	0.05%	423
2021 Q3	$121K	Buy	+13,912	New	+$125K	0.08%	414

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's IMVT Position: Q2 2026 in Review

Fox Run Management opened a new position in Immunovant (IMVT) in Q2 2026: 34,827 shares worth $1.34M. The stake represents 0.22% of the portfolio and ranks #93 among its holdings. This is a return to the name: Fox Run Management previously reported a position in IMVT as recently as Q1 2025.

Fox Run Management first reported a position in IMVT in Q3 2021 and has held it in 7 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Fox Run Management held 34,827 shares of Immunovant worth $1.34M as of Q2 2026.
Immunovant was a new Fox Run Management position in Q2 2026.
Immunovant made up 0.22% of Fox Run Management's portfolio in Q2 2026, its #93 holding.
Fox Run Management first reported a position in Immunovant in Q3 2021 and has held it in 7 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.